Identification of two distinct regions of allelic imbalance on chromosome 18Q in metastatic prostate cancer.

Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
International Journal of Cancer (Impact Factor: 5.01). 04/2000; 85(5):654-8.
Source: PubMed

ABSTRACT Like most cancers, prostate cancer (CaP) is believed to be the result of the accumulation of genetic alterations within cells. Previous studies have implicated numerous chromosomal regions with elevated rates of allelic imbalance (AI), using mostly primary CaPs with an unknown disease outcome. These regions of AI are proposed sites for tumor suppressor genes. One of the regions previously implicated as coding for at least one tumor suppressor gene is the long arm of chromosome 18 (18q). To confirm this observation, as well as to narrow the critical region for this putative tumor suppressor, we analyzed 32 metastatic CaP specimens for AI on chromosome 18q. Thirty-one of these 32 specimens (96.8%) exhibited AI at one or more loci on chromosome 18q. Our analysis using 17 polymorphic markers revealed statistically significant AI on chromosome 18q at 3 markers, D18S35, D18S64 and D18S461. Using these markers as a guide, we have been able to identify 2 distinct minimum regions of AI on 18q. The first region is between the genetic markers D18S1119 and D18S64. The second region lies more distal on the long arm of the chromosome and is between the genetic markers D18S848 and D18S58. To determine if 18q loss is a late event in the progression of CaP, we also examined prostatic intraepithelial neoplasia (PIN) and primary prostate tumors from 17 patients for AI with a subset of 18q markers. We found significantly higher AI in the metastatic samples. Our results are consistent with 18q losses occurring late in CaP progression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytogenetic, molecular cytogenetic, and molecular studies of prostate cancer have produced a large volume of data about chromosomal loci that are aberrant in prostate cancer. The cumulative data on prostate cancer reveal allelic losses on chromosome arms 2q, 3p, 5q, 6q, 7q, 8p, 9p, 10p, 10q, 11p, 11q, 12p, 13q, 16q, 17p, 17q, 18q, and 21q, but there is a great deal of variability between studies. In most cases, the frequency of allelic loss is higher in metastatic tissues or hormone-refractory tumors than in primary tumors. There also seem to be discrepancies in the genetic findings depending on methods employed. Molecular genetic studies, using polymerase chain reaction (PCR) analysis of microsatellite markers, demonstrated allelic loss at 7q31.1, whereas fluorescence in situ hybridization analysis showed a gain at the same region. Com-mon sites of allelic loss that are consistently observed by various methods seem to exist on chromosome arms 8p, 10q, 13q, and 16q. PTEN/MMAC1 has been identified on 10q23.3 and was found to be frequently mutated in advanced prostate cancer. Other regions are also considered to harbor genes associated with the development and progression of prostate cancer, and these could be included in the diagnostic methods for the substaging of prostate cancer.
    International Journal of Clinical Oncology 11/2000; 5(6):345-354. DOI:10.1007/PL00012062 · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The process of cancer and prostate cancer metastasis is complex and requires fundamental changes to the behaviour of the parent cell. While the stage at which essential mutations for prostate cancer metastasis occur remains controversial, it is likely, based on current evidence, that an accumulation of genetic damage is required. However, the study of cancer metastasis is clearly dependent on the availability of suitable in vitro and in vivo models. Not every model represents the full in vivo situation in man, but a combination of these models is now becoming available in prostate cancer and should allow a more detailed assessment of the specific genes involved in metastasis and the preferential adhesion in bone. Identification of specific genes associated with particular pathology has also taken tremendous steps forward in the last few years. Differential expression analysis, of both the RNA and also protein levels are providing new targets for therapy, specifically directed against metastatic disease. However, for longer term prospects the ability to detect metastasis in a simple blood sample would offer the most hope of permanent treatment or indeed cure. Based on serum profiling, such methods should soon be available to the oncologist in the clinic. On-line catalogues of genes whose expression is perturbed in metastatic processes offer the first clues to the key events in this complex biological process. It is perhaps from these catalogues improved animal models and indeed the more global analysis of patient samples from bio-banks that the key events and a genetic basis will be identified.
    05/2007: pages 21-61;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Zahlreiche Erkenntnisse in der Prostatakarzinomforschung basieren auf Zellkulturergebnissen. Neuere genomische Untersuchungen zeigen jedoch, dass verwendete permanente Prostatakarzinomzelllinien sich deutlich von dem klinisch relevanten, primären Prostatakarzinom unterscheiden und damit die Übertragbarkeit dieser Zellkulturergebnisse auf die Klinik nur bedingt gegeben ist. Das Arbeiten mit Primärzellkulturen aus Gewebestückchen von Prostatektomiepräparaten bietet eine sehr gute Alternative, doch die Etablierung von Primärkulturen gestaltet sich schwierig und recht aufwändig. In dieser Arbeit wurde ein Primärzellkulturmodell mit einem Invasionssystem kombiniert. Hiermit gelang es nicht nur invasiv wachsende Zellpopulationen aus Primärkulturen zu selektionieren, sondern auch diese Zellen in einem 3D-Modell unter der Ausbildung von Sphäroiden weiter zu kultivieren. Zur Charakterisierung dieser Zellpopulation haben wir vergleichende genomische Hybridisierungen durchgeführt, die zahlreiche genetische Alterationen aufzeigen. Das hier dargestellte Modell ermöglicht es erstmalig, invasive Zellklone aus primärem Prostatakarzinomgewebe zu gewinnen und durch Kultivierung für weitere Untersuchungen zu verwenden.
    Der Urologe 09/2008; 47(9):1199-1204. DOI:10.1007/s00120-008-1835-x · 0.44 Impact Factor